Targeting FLIP and Mcl‐1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL
- 6 November 2012
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 229 (3) , 410-421
Abstract
The multikinase inhibitor sorafenib is highly effective against certain types of cancer in the clinic and prevents colon cancer cell proliferation in vitro. Non-steroidal anti-inflammatory drugs, such as acetylsalicylic acid (aspirin), have shown activity against colon cancer cells. The aims of this study were to determine whether the combination of aspirin with sorafenib has enhanced anti-proliferative effects and increases recombinant human tumour necrosis factor-related apoptosis-inducing ligand (rhTRAIL)-induced apoptosis in the human SW948, Lovo, Colo205, Colo320, Caco-2 and HCT116 colon cancer cell lines. In four cell lines, aspirin strongly stimulated the anti-proliferative effects of sorafenib (∼four-fold enhancement) by inducing cell cycle arrest. Furthermore, combining low doses of aspirin (≤ 5 mm) and sorafenib (≤ 2.5 µm) greatly sensitized TRAIL-sensitive and TRAIL-resistant colon cancer cells to rhTRAIL, much more potently than either drug combined with rhTRAIL. The increase in rhTRAIL sensitivity was due to inhibition of FLIP and Mcl-1 protein expression following aspirin and sorafenib co-treatment, as confirmed by knock-down studies. Next, the clinical relevance of targeting FLIP and Mcl-1 in colon cancer was examined. Using immunohistochemistry, we found that Mcl-1 expression was significantly increased in colon adenoma and carcinoma patient material compared to healthy colonic epithelium, similar to the enhanced FLIP expression we recently observed in colon cancer. These results underscore the potential of combining low doses of aspirin with sorafenib to inhibit proliferation and target the anti-apoptotic proteins FLIP and Mcl-1 in colon cancer cells. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 60 references indexed in Scilit:
- Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trialsThe Lancet, 2012
- Are we ready to recommend aspirin for cancer prevention?The Lancet, 2012
- TNF‐related apoptosis‐inducing ligand cooperates with NSAIDs via activated Wnt signalling in (pre)malignant colon cellsThe Journal of Pathology, 2010
- Mitochondria and cell death: outer membrane permeabilization and beyondNature Reviews Molecular Cell Biology, 2010
- Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-α and TRAIL-initiated apoptotic signalsExperimental Hematology, 2008
- BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosisMolecular Cancer Therapeutics, 2008
- Targeting TRAIL death receptorsCurrent Opinion in Pharmacology, 2008
- Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell linesBritish Journal of Cancer, 2003
- A Randomized Trial of Aspirin to Prevent Colorectal AdenomasNew England Journal of Medicine, 2003
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001